Tyrosine kinase inhibitor (TKI) keratitis is an ocular complication of certain antineoplastic medications, primarily those that inhibit the epidermal growth factor receptor (EGFR). This activity will focus on the etiology, epidemiology, pathophysiology, clinical presentation, and management of TKI keratitis. It also highlights the role of the interprofessional team in managing patients with this condition.

**Objectives:**
- Describe the etiology of TKI keratitis. 
- Explain the pathophysiology of TKI keratitis. 
- Review the differences in TKI keratitis from other common causes of keratitis.
- Outline the prognosis of TKI keratitis.